Recombinant Mouse Interleukin-22/IL-22 (E. coli)

Cat.No.: C047

Recombinant Mouse IL-22 (E. coli)
Description
Recombinant Mouse Interleukin-22 is produced by our E.coli expression system and the target gene encoding Leu34-Val179 is expressed.
Accession #:Q9JJY9
Known as:Interleukin-22; IL-22; IL-10-Related T-Cell-Derived-Inducible Factor; IL-TIF; IL-TIF Alpha; Interleukin-22a; IL-22a; Il22; Il22a; Iltif; Iltifa
Formulation
Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.0.
Quality Control
Purity:Greater than 95% as determined by reducing SDS-PAGE.
BioActivity:Measured by its ability to induce IL-10 secretion in COLO 205 human colorectal adenocarcinoma cells.
Endotoxin:Less than 0.1 ng/?g (1 EU/
Reconstitution
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Background
Interleukin-22 (IL-22) was initially identified as a gene induced by IL-9 in mouse T cells and mast cells. Mouse IL-22 cDNA encodes a 179 amino acid residue protein with a putative 33 amino acid signal peptide that is cleaved to generate a 147 amino acid mature protein that shares approximately 79% and 22% sequence identity with human IL22 and IL10, respectively. IL22 has been shown to activate STAT-1 and STAT-3 in several hepatoma cell lines and up-regulate the production of acute phase proteins. IL-22 is produced by normal mouse T cells upon Con A activation. Mouse IL-22 expression is also induced in various organs upon lipopolysaccharide injection, suggesting that IL-22 may be involved in inflammatory responses. The functional IL-22 receptor complex consists of two receptor subunits, IL-22R (previously an orphan receptor named CRF2-9) and IL-10Rβ (previously known as CRF2-4), belonging to the class II cytokine receptor family.
Publication
Extract from indigo naturalis and a process for preparing the same Lin Yin-ku, et al. (Galderma S.A. patent:10251926 43564)+
The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.
Pharmaceutical composition comprising refined indigo naturalis extract and the use thereof Chantalat Laurent, et al. (Galderma S.A. patent:10232006 43543)+
A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.
PHARMACEUTICAL COMPOSITION COMPRISING REFINED INDIGO NATURALIS EXTRACTS AND THE USE THEREOF Chantalat Laurent, et al. (Galderma S.A. patent:US20190160128 2019)+
A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.
EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME Lin Yin-ku, et al. (Galderma S.A. patent:US20190224264 2019)+
The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.
EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME Lin Yin-ku, et al. (Galderma S.A. patent:US20180099020 2018)+
The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.
Extract from indigo naturalis and a process for preparing the same Lin Yin-ku, et al. (Galderma S.A. patent:9861673 2018)+
The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.
EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME Lin Yin-ku, et al. (Galderma S.A. patent:US20170266248 2017)+
The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.
PHARMACEUTICAL COMPOSITION AND THE USE THEREOF Chantalat Laurent, et al. (Galderma S.A. patent:US20170304381 2017)+
A pharmaceutical composition, as well as the use of composition in medical applications, are described.

Send Message